Literature DB >> 14662345

Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation.

Glenn P Niemeyer1, Mary K Boudreaux, Susan A Goodman-Martin, Christine M Monroe, David A Wilcox, Clinton D Lothrop.   

Abstract

OBJECTIVE: The purpose of this study was to determine if nonmyeloablative bone marrow transplantation would induce stable hematopoietic chimerism that would correct the bleeding diathesis associated with type I Glanzmann's thrombasthenia (GT).
METHODS: Three young dogs (less than 12 weeks of age) with GT were transplanted with DLA-matched bone marrow from littermates. Recipients received a sublethal dose (200 cGy) of total-body irradiation (TBI) prior to infusion with bone marrow (1-4 x 10(8) cells/kg). Recipient dogs were immunosuppressed with cyclosporine (15 mg/kg) and mycophenolate mofetil (10 mg/kg). Chimerism was determined by quantitation of donor microsatellite repeat polymorphisms in peripheral blood DNA and by flow cytometry to detect the presence of glycoproteins IIb and IIIa on platelets. Platelet function was assessed by a clot retraction test.
RESULTS: One dog died one week posttransplant due to hemorrhage. Another dog died four weeks posttransplant from an unrecognized congenital heart defect and complications due to canine distemper virus infection. At the time of death, microsatellite analysis indicated 35 to 50% chimerism. Flow cytometry showed 20% of circulating platelets positive for glycoproteins IIb and IIIa. The third dog is alive and doing well approximately two years posttransplant. Hematopoietic chimerism has been sustained at 35 to 60% with approximately 30% of the platelets positive for glycoproteins IIb and IIIa. Platelet function is normal based on clot retraction. The animal does not have clinical signs of bleeding.
CONCLUSIONS: These observations suggest that GT and perhaps other severe inherited platelet disorders can be corrected using nonmyeloablative bone marrow transplantation to establish partial chimerism with normal platelets in the platelet compartment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662345     DOI: 10.1016/j.exphem.2003.09.005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

1.  Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs.

Authors:  Juan Fang; Eric S Jensen; Mary K Boudreaux; Lily M Du; Troy B Hawkins; Sevasti B Koukouritaki; Kenneth Cornetta; David A Wilcox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

Review 2.  Megakaryocyte- and megakaryocyte precursor-related gene therapies.

Authors:  David A Wilcox
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

3.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

4.  Haploidentical in utero hematopoietic cell transplantation improves phenotype and can induce tolerance for postnatal same-donor transplants in the canine leukocyte adhesion deficiency model.

Authors:  William H Peranteau; Todd E Heaton; Yu-Chen Gu; Susan W Volk; Thomas R Bauer; Keith Alcorn; Laura M Tuschong; Mark P Johnson; Dennis D Hickstein; Alan W Flake
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

5.  Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Authors:  Lily M Du; Paquita Nurden; Alan T Nurden; Timothy C Nichols; Dwight A Bellinger; Eric S Jensen; Sandra L Haberichter; Elizabeth Merricks; Robin A Raymer; Juan Fang; Sevasti B Koukouritaki; Paula M Jacobi; Troy B Hawkins; Kenneth Cornetta; Qizhen Shi; David A Wilcox
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 6.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.